Karyopharm Therapeutics Inc (NASDAQ: KPTI) kicked off on Monday, down -6.37% from the previous trading day, before settling in for the closing price of $0.72. Over the past 52 weeks, KPTI has traded in a range of $0.58-$1.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 56.57% over the last five years. While this was happening, its average annual earnings per share was recorded 42.51%. With a float of $115.36 million, this company’s outstanding shares have now reached $125.30 million.
The firm has a total of 325 workers. Let’s measure their productivity. In terms of profitability, gross margin is 95.68%, operating margin of -84.86%, and the pretax margin is -58.73%.
Karyopharm Therapeutics Inc (KPTI) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Karyopharm Therapeutics Inc is 8.58%, while institutional ownership is 47.15%. The most recent insider transaction that took place on Jan 06 ’25, was worth 3,175. In this transaction President and CEO of this company sold 4,055 shares at a rate of $0.78, taking the stock ownership to the 1,124,257 shares. Before that another transaction happened on Dec 04 ’24, when Company’s President and CEO sold 3,620 for $0.81, making the entire transaction worth $2,932. This insider now owns 1,128,312 shares in total.
Karyopharm Therapeutics Inc (KPTI) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.23 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.51% per share during the next fiscal year.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Trading Performance Indicators
Take a look at Karyopharm Therapeutics Inc’s (KPTI) current performance indicators. Last quarter, stock had a quick ratio of 2.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.14, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.72 in one year’s time.
Technical Analysis of Karyopharm Therapeutics Inc (KPTI)
Analysing the last 5-days average volume posted by the [Karyopharm Therapeutics Inc, KPTI], we can find that recorded value of 0.71 million was lower than the volume posted last year of 0.98 million. As of the previous 9 days, the stock’s Stochastic %D was 42.50%. Additionally, its Average True Range was 0.07.
During the past 100 days, Karyopharm Therapeutics Inc’s (KPTI) raw stochastic average was set at 16.74%, which indicates a significant decrease from 36.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 121.26% in the past 14 days, which was higher than the 81.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7798, while its 200-day Moving Average is $0.9121. Now, the first resistance to watch is $0.7242. This is followed by the second major resistance level at $0.7755. The third major resistance level sits at $0.8111. If the price goes on to break the first support level at $0.6373, it is likely to go to the next support level at $0.6017. Should the price break the second support level, the third support level stands at $0.5504.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Key Stats
The company with the Market Capitalisation of 84.90 million has total of 126,191K Shares Outstanding. Its annual sales at the moment are 146,030 K in contrast with the sum of -143,100 K annual income. Company’s last quarter sales were recorded 38,780 K and last quarter income was -32,070 K.
